European Journal of Obstetrics and Gynecology and Reproductive Biology: X最新文献

{"title":"Implementation of antepartum preterm birth interventions: A scoping review","authors":"Etoroabasi Ekpe ,&nbsp;Jason Collier ,&nbsp;Benjamin H. Chi ,&nbsp;Divya Mallampati","doi":"10.1016/j.eurox.2025.100373","DOIUrl":"10.1016/j.eurox.2025.100373","url":null,"abstract":"<div><div>While antenatal recommendations regarding preterm birth are essential to preventing neonatal morbidity and mortality, implementation of these recommendations underscore how health system capacity and systemic factors, such as access and quality, greatly influence their utilization. To date, there is limited synthesis focused on the implementation of antenatal preterm birth interventions. Our objectives were to focus on implementation science studies intended to 1) increase referral mechanisms of pregnant people to higher levels of care where the management of preterm labor or delivery is possible and 2) map the implementation of preterm birth interventions, including the administration of antenatal corticosteroids, magnesium sulfate, and antibiotics. We conducted a scoping review using key terms in online databases to identify implementation science strategies focused on referral mechanisms and preterm birth interventions. Studies were selected based on the strength of existing literature. Quality assessment was conducted with the Mixed Methods Assessment Tool (MMAT). To evaluate study intervention strategies, we used the RE-AIM framework – a comprehensive evaluative framework composed of 5 dimensions: reach, effectiveness, adoption, implementation, and maintenance. Of the 1178 articles that were screened, 18 were evaluated, and 13 included in this review. The studies were conducted in 12 countries, the majority of which were lower to lower-middle income countries. Designs ranged from quantitative non-randomized studies to qualitative and mixed methods. By using the RE-AIM framework, we found that there was heterogeneity among the studies with regards to whether they addressed reach, effectiveness, adoption, implementation, or maintenance. Common interventions for referring pregnant women to higher levels of care included the use of skilled birth attendants, referral systems, financial incentives, quality of emergency obstetric care, and community health workers. Implementation studies on preterm birth interventions with corticosteroids or magnesium sulfate focused on increasing awareness and knowledge of evidence-based practices using care bundles, online or in person training sessions, focus groups, interviews, and surveys. Overall, we identified how implementation studies increased the use of antenatal corticosteroids and magnesium sulfate and also identified how community health workers, skilled birth attendants, and referral systems can reduce complications from preterm birth. With further review of implementation science research, implementation science can be used to further understand and integrate evidence based-knowledge into practice in a consistent and reproducible matter.</div></div>","PeriodicalId":37085,"journal":{"name":"European Journal of Obstetrics and Gynecology and Reproductive Biology: X","volume":"25 ","pages":"Article 100373"},"PeriodicalIF":1.5,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143452998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decreasing trend of gastroschisis prevalence in the United States from 2014 through 2022: Is attributed to declining birth rates in young, high-risk gravidae","authors":"Hiba J. Mustafa ,&nbsp;Nikan Zargarzadeh ,&nbsp;Kevin L. Moss ,&nbsp;May Abiad ,&nbsp;Brian Gray ,&nbsp;Kjersti M. Aagaard ,&nbsp;Terry L. Buchmiller ,&nbsp;Erin E. Perrone ,&nbsp;Alireza A. Shamshirsaz","doi":"10.1016/j.eurox.2025.100374","DOIUrl":"10.1016/j.eurox.2025.100374","url":null,"abstract":"<div><h3>Objectives</h3><div>To investigate the prevalence trend of gastroschisis in the United States between 2014 and 2022.</div></div><div><h3>Methods</h3><div>A cross-sectional retrospective analysis of the Centers for the United States live births between 2014 and 2022. Pregnancies and neonatal singleton live births with documented isolated gastroschisis were included. Neonates with other major congenital anomalies and known chromosomal abnormalities were excluded. Prevalence per 10,000 live births along with 95 % confidence intervals was estimated.</div></div><div><h3>Results</h3><div>Among 32,088,301 singleton live births, 6804 cases of isolated gastroschisis were identified (Point prevalence: 2 in 10,000 live births). A significant decline in gastroschisis prevalence was observed, decreasing from 2.86 per 10,000 live births in 2014–1.55 per 10,000 live births in 2022 (<em>P</em> &lt; 0.001). The risk of gastroschisis was significantly higher in teen and nulliparous gravidae, with prepregnancy tobacco use, and among socially vulnerable populations (underweight, &lt; 12th-grade education, Medicaid, non-Hispanic Indigenous Americans). The drop in gastroschisis births from 2014 to 2022, compared to non-gastroschisis births, is more significant in maternal age &lt; 20 years, nulliparous, BMI &lt; 18.5, and in smokers prior to pregnancy than in the overall population (P = 0.02, 0.0008, &lt;0.0001, &lt;0.0001, and 0.01 respectively). All of the associated maternal factors had a significant decline in prevalence (<em>P</em> &lt; 0.001), which may influence the decreasing trend of gastroschisis. There was no perceived considerable impact of the COVID-19 pandemic on gastroschisis trends.</div></div><div><h3>Conclusions</h3><div>The study highlights a notable decline in gastroschisis prevalence mostly attributable to a declining birth rate in the highest at-risk strata, suggesting recent increases in birth rates among these at-risk gravidae may reverse the trend of declining gastroschisis disease prevalence. These findings support the need for ongoing further research to understand effective means of sustaining this decreasing trend.</div></div>","PeriodicalId":37085,"journal":{"name":"European Journal of Obstetrics and Gynecology and Reproductive Biology: X","volume":"25 ","pages":"Article 100374"},"PeriodicalIF":1.5,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143419902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of an exam-indicated cerclage before 24 weeks of gestation to prevent preterm birth: A systematic review and meta-analysis","authors":"Bouchra Koullali ,&nbsp;Charlotte E. van Dijk ,&nbsp;Charlotte E. Kleinrouweler ,&nbsp;Jacqueline C.E.J.M.P. Limpens ,&nbsp;Ben W. Mol ,&nbsp;Martijn A. Oudijk ,&nbsp;Eva Pajkrt","doi":"10.1016/j.eurox.2025.100372","DOIUrl":"10.1016/j.eurox.2025.100372","url":null,"abstract":"<div><div>The effect of an exam-indicated cerclage (EIC) remains uncertain due to limited evidence from reviews covering pregnancies beyond this timeframe. With the 24-week mark serving as an international threshold for neonatal care initiation, the aim of this systematic review was to evaluate the available literature on the effectiveness of an EIC before 24 weeks of gestation. MEDLINE, EMBASE, Web of Science, CENTRAL, clinicaltrials.gov and WHO-ICTRP were searched for randomized controlled trials, cohort and case-control studies comparing EIC with expectant management in singleton pregnancies with cervical dilation ≤ 5 cm between 14 and 24 weeks of gestation to prevent preterm birth (PTB) &lt; 37 weeks of gestation. Secondary outcomes included obstetrical and neonatal outcomes. Quality assessment was preformed using Newcastle-Ottawa Scale. Analyses were conducted using R(studio) version 3.6.1. and outcomes stated as odds ratios (OR) with 95 % confidence intervals (CI). Prospero: #CRD42019137400. The search yielded 787 potential studies. Four studies non-randomized (retrospective) could be included. Quality assessment showed overall good quality. The main weaknesses were retrospective designs, small sample sizes and the poor comparability of the intervention and control groups. The study population resulted in 215 women, among whom 163 (76 %) underwent cerclage placement and 52 (24 %) were expectantly managed. EIC compared with expectant management was associated with significant lower rates of PTB before 37 weeks (71.2 % vs 94.2 %; OR 0.11; 95 % CI 0.03–0.35), 34 weeks (49.1 % vs 86.5 %; OR 0.10; 95 % CI 0.03–0.31), 32 weeks (43.0 % vs 80.0 %; OR 0.13; 95 % CI 0.04–0.43), 28 weeks (43.0 % vs 75.0 %; OR 0.19; 95 % CI 0.07–0.51) and 24 weeks (23.3 % vs 50 %; OR 0.29; 95 % CI 0.13–0.65) of gestation, significant prolongation of the pregnancy (mean difference 39.14 days; 95 %CI 30.58–47.71; p-value &lt;0.0001) and a greater gestational age at delivery (mean difference 4.91 weeks; 95 % CI 2.32–7.49; p-value 0.0002) compared to expectant management. The current literature suggests that EIC before 24 weeks of gestation is associated with improved pregnancy outcomes compared to expectant management. The results are limited by the lack of randomised trials and studied neonatal outcomes plus the potential for bias in the included studies.</div></div>","PeriodicalId":37085,"journal":{"name":"European Journal of Obstetrics and Gynecology and Reproductive Biology: X","volume":"25 ","pages":"Article 100372"},"PeriodicalIF":1.5,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143427562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The single-cell immune profile throughout gestation and its potential value for identifying women at risk for spontaneous preterm birth","authors":"Dorien Feyaerts ,&nbsp;Maïgane Diop ,&nbsp;Jose Galaz ,&nbsp;Jakob F. Einhaus ,&nbsp;Petra C. Arck ,&nbsp;Anke Diemert ,&nbsp;Virginia D. Winn ,&nbsp;Mana Parast ,&nbsp;Cynthia Gyamfi-Bannerman ,&nbsp;Jelmer R. Prins ,&nbsp;Nardhy Gomez-Lopez ,&nbsp;Ina A. Stelzer","doi":"10.1016/j.eurox.2025.100371","DOIUrl":"10.1016/j.eurox.2025.100371","url":null,"abstract":"<div><div>Precisely timed immune adaptations, observed in the maternal circulation, underpin the notion of an immune clock of human pregnancy that supports its successful progression and completion at delivery. This immune clock is divided into three immunological phases, with the first phase starting at the time of conception and implantation, shifting into the second phase that supports homeostasis and tolerance throughout pregnancy, and culminating in the last phase of labor and parturition. Disruptions of this immune clock are reported in pregnancy complications such as spontaneous preterm birth. However, our understanding of the immune clock preceding spontaneous preterm birth remains scattered. In this review, we describe the chronology of maternal immune cell adaptations during healthy pregnancies and highlight its disruption in spontaneous preterm birth. With a focus on single-cell cytometric, proteomic and transcriptomic approaches, we review recent studies of term and spontaneous preterm pregnancies and discuss the need for future prospective studies aimed at tracking pregnancies longitudinally on a multi-omic scale. Such studies will be critical in determining whether spontaneous preterm pregnancies progress at an accelerated pace or follow a preterm-intrinsic pattern when compared to those delivered at term.</div></div>","PeriodicalId":37085,"journal":{"name":"European Journal of Obstetrics and Gynecology and Reproductive Biology: X","volume":"25 ","pages":"Article 100371"},"PeriodicalIF":1.5,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143427645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Randomized controlled trial of 4.0 mg versus 0.4 mg folic acid supplementation: Follow-up of children at 1 year of age","authors":"Renata Bortolus ,&nbsp;Francesca Filippini ,&nbsp;Sonia Cipriani ,&nbsp;Daniele Trevisanuto ,&nbsp;Federico Marchetti ,&nbsp;Pierpaolo Mastroiacovo ,&nbsp;Fabio Parazzini ,&nbsp;Francesco Cavallin ,&nbsp;on behalf of the Italian Folic Acid Trial Study Group","doi":"10.1016/j.eurox.2025.100370","DOIUrl":"10.1016/j.eurox.2025.100370","url":null,"abstract":"<div><h3>Objective and study design</h3><div>This 1-year follow-up study reports the results on the health status, visits to the paediatrician and hospitalizations of children born from the women recruited in the main randomized controlled trial (RCT) that investigated the effect of periconception folic acid (FA) supplementation of 4.0 mg/day on reducing adverse reproductive outcomes.</div></div><div><h3>Methods</h3><div>The health status of livebirths was evaluated by a trained health care provider (HCP) through a phone interview with the paediatrician (at 1–3–12 months of age) and with the parents (at 12 months of age), using a structured data collection form.</div></div><div><h3>Results</h3><div>Information at 1 year of life could be obtained for 347/376 (92.3 %) newborns included in the original RCT. No statistically significant differences were observed between the two groups regarding weight, health problems, hospitalizations from birth to 1 year of life and developmental milestones, as well as accesses to the emergency ward and parents’worries. Breastfeeding differed significantly at 1, 3 and 12 months of life, with higher proportion of exclusive breastfeeding in the 4.0 mg FA Group.</div></div><div><h3>Conclusion</h3><div>The findings suggest that the periconception FA supplementation of 4.0 mg/day versus 0.4 mg/day, does not affect the health status and hospitalizations from birth to 1 year of life, as well as normal child’s developmental milestones at 1 year of life. The increase in exclusive breastfeeding in the 4.0 mg FA group needs further investigation.</div></div>","PeriodicalId":37085,"journal":{"name":"European Journal of Obstetrics and Gynecology and Reproductive Biology: X","volume":"25 ","pages":"Article 100370"},"PeriodicalIF":1.5,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143387233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of oxytocin, sublingual, and intrauterine misoprostol on blood loss in cesarean delivery: A randomized clinical trial","authors":"Mahdieh Masoumzadeh ,&nbsp;Vahideh Rahmani ,&nbsp;Manizheh Sayyah-Melli ,&nbsp;Anis Sani","doi":"10.1016/j.eurox.2025.100369","DOIUrl":"10.1016/j.eurox.2025.100369","url":null,"abstract":"<div><h3>Background</h3><div>The efficacy of different uterotonic agents is yet to be determined.</div></div><div><h3>Methods</h3><div>This was a randomized clinical trial on 240 pregnant mothers with a history of cesarean section in three groups: A: sublingual misoprostol and oxytocin, B: intrauterine misoprostol and oxytocin, and C: a higher dose of oxytocin alone. The intrapartum blood loss and the estimated blood loss within 24 h after surgery were compared between the groups.</div></div><div><h3>Results</h3><div>The baseline characteristics showed no significant differences among the groups. The volume of blood loss during surgery and within 24 h postpartum did not differ significantly among the groups (A: 230.72 ± 97.30, B: 245.60 ± 88.50, C: 229.02 ± 109.78, p = 0.115, and A: 2023.84 ± 480.08, B: 2045.26 ± 598.99, C: 2025.61 ± 538.93, p = 0.819, respectively).</div></div><div><h3>Conclusion</h3><div>Intrauterine misoprostol plus oxytocin, sublingual misoprostol plus oxytocin and a higher dose of oxytocin did not show any significant difference in the amount of blood loss during surgery and within 24 h post-operation.</div></div>","PeriodicalId":37085,"journal":{"name":"European Journal of Obstetrics and Gynecology and Reproductive Biology: X","volume":"25 ","pages":"Article 100369"},"PeriodicalIF":1.5,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143327423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"To do or not to do? – Endometrial biopsy in younger women with abnormal uterine bleeding","authors":"Sandra Lynn Jaya-Bodestyne ,&nbsp;Marlene Samantha Goh ,&nbsp;Madeline Chan Hiu Gwan ,&nbsp;Sonali Prashant Chonkar ,&nbsp;Khurshid Merchant ,&nbsp;Manisha Mathur","doi":"10.1016/j.eurox.2025.100368","DOIUrl":"10.1016/j.eurox.2025.100368","url":null,"abstract":"<div><h3>Objective</h3><div>Abnormal uterine bleeding (AUB) can be associated with underlying endometrial pathology. The current existing guidelines discuss the role of endometrial biopsy in women 40 years old and above, however, there are no clear recommendations for younger women. This study aims to identify the factors that increase the risk of endometrial pathology in women below 40 years of age presenting with AUB for consideration of endometrial biopsy.</div></div><div><h3>Methods</h3><div>We conducted a retrospective observational study reviewing the records of 464 women aged under 40 years old who underwent endometrial biopsy for AUB. The data analysis included demographics, investigations undertaken, ultrasound findings, biopsy results, and treatment. Multivariable analysis was performed using modified Poisson regression models to compare women with endometrial hyperplasia (EH) (with or without atypia) and endometrial cancer (EC), to those with benign pathology, to identify risk factors for endometrial pathology.</div></div><div><h3>Results</h3><div>In our study, 71.3 % of women had a benign histology, 22.8 % had EH with and without atypia and 2.2 % of women had a diagnosis of EC. A BMI ≥ 30 (RR 1.76, p = 0.002), nulliparity (RR 1.84, p = 0.001), ultrasound findings of thickened endometrium ≥ 15 mm (RR 1.39, p = 0.048) and cystic spaces in the endometrium (RR 1.83, p &lt; 0.001) were identified as significant risk factors after a multivariate analysis. A combination of at least 3 of these risk factors had a cumulative increased risk of EH/EC (RR 3.80, p &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>Endometrial biopsy in younger women with AUB should be carefully considered on a case-by-case basis and reserved for those with risk factors for a serious endometrial pathology.</div></div>","PeriodicalId":37085,"journal":{"name":"European Journal of Obstetrics and Gynecology and Reproductive Biology: X","volume":"25 ","pages":"Article 100368"},"PeriodicalIF":1.5,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143174136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of menopausal hot flushes. Recommendations from the Spanish Menopause Society","authors":"M. Fasero ,&nbsp;M. Sanchez ,&nbsp;L. Baquedano ,&nbsp;I. Gippini ,&nbsp;D. Fuentes ,&nbsp;C. Navarro ,&nbsp;E. Beltrán ,&nbsp;M. Lilue ,&nbsp;I. Porcel ,&nbsp;C. Pingarrón ,&nbsp;M. Herrero ,&nbsp;P. Romero ,&nbsp;T. Ortega ,&nbsp;E. Carretero ,&nbsp;S. Palacios ,&nbsp;N. Mendoza ,&nbsp;P.J. Coronado","doi":"10.1016/j.eurox.2025.100366","DOIUrl":"10.1016/j.eurox.2025.100366","url":null,"abstract":"<div><div>This project aims to develop recommendations for treating vasomotor symptoms (VMS) based on the Cervantes short-form scale score (menopausal domain) using the best available evidence. A total of 166 studies were selected: 108 randomized controlled trials, 23 systematic reviews, 3 reviews, 3 meta-analyses, 11 case-control studies, 9 observational studies, and 12 transversal studies. To achieve this objective, a series of PICO (Patient, Intervention, Comparison, and Outcome) questions have been established for the treatment of VMS. We evaluate the quality of the scientific evidence and, with the findings, create a decision framework to treat hot flashes based on the Cervantes short-form scale score.</div></div>","PeriodicalId":37085,"journal":{"name":"European Journal of Obstetrics and Gynecology and Reproductive Biology: X","volume":"25 ","pages":"Article 100366"},"PeriodicalIF":1.5,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143174125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of adult stem cells in obstetrics and gynecology: A scoping review","authors":"Andi Kurniadi ,&nbsp;Muhammad Ary Zucha ,&nbsp;Ardhanu Kusumanto ,&nbsp;Siti Salima ,&nbsp;Ali Budi Harsono","doi":"10.1016/j.eurox.2025.100367","DOIUrl":"10.1016/j.eurox.2025.100367","url":null,"abstract":"<div><h3>Background</h3><div>Advancements in regenerative medicine have led to the applicability of stem cell technology in various diseases. Stem cells that have self-renewable abilities may differentiate into several cell types to provide therapeutic potential. Among different stem cells, adult stem cells are considered as the safest with remarkable potential for therapeutic application. In this review, we provide current available evidence regarding the application of adult stem cells in medicine, especially in the field of obstetrics and gynecology.</div></div><div><h3>Objective</h3><div>This scoping review aims to map and describe the current research on adult stem cell application in obstetrics and gynecology.</div></div><div><h3>Methods</h3><div>We performed a systematic search on PubMed, Google Scholar, and Cochrane Library in August 2024 to identify research articles involving adult stem cells in the field of obstetrics and gynecology. We used the Deduplicate website to filter articles based on keywords that met our inclusion and exclusion criteria. The results were presented based on recommendations from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews.</div></div><div><h3>Results</h3><div>We found 42 articles that met the inclusion criteria. Some studies were clinical studies, whereas the majority were preclinical studies. We categorized the articles into clinical and preclinical studies to understand their applicability in human subjects.</div></div><div><h3>Conclusions</h3><div>Adult stem cell therapy is a candidate treatment for several pathologies in obstetrics and gynecology. The promising results of adult stem cell therapy, especially in degenerative gynecologic diseases, may lead to further application of the technology in the near future.</div></div>","PeriodicalId":37085,"journal":{"name":"European Journal of Obstetrics and Gynecology and Reproductive Biology: X","volume":"25 ","pages":"Article 100367"},"PeriodicalIF":1.5,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143174884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between Apolipoprotein L1 genetic variants and risk of preeclampsia and preterm birth among U.S. Black women","authors":"Shanshan Sheehy ,&nbsp;David Friedman ,&nbsp;Chunyu Liu ,&nbsp;Kathryn L. Lunetta ,&nbsp;Gary Zirpoli ,&nbsp;Julie R. Palmer","doi":"10.1016/j.eurox.2025.100365","DOIUrl":"10.1016/j.eurox.2025.100365","url":null,"abstract":"<div><h3>Background</h3><div>Preeclampsia and preterm birth disproportionally affects Black women, but the current understanding of genetic predisposition to preeclampsia and preterm birth is rudimentary. It has been hypothesized that carriers of high-risk genetic variants in the apolipoprotein L1 gene (<em>APOL1</em>) may have an increased risk of preeclampsia and preterm birth. These genetic variants are found only among individuals of recent African ancestry. Previous studies have been small and have yielded inconsistent results.</div></div><div><h3>Objective</h3><div>To examine whether <em>APOL1</em> genetic variants are associated with risk of preeclampsia or preterm birth.</div></div><div><h3>Study design</h3><div>We conducted a retrospective case-control study of 6616 Black women from the Black Women’s Health Study, a cohort of self-identified Black women in the U.S. Genotype data on <em>APOL1</em> risk alleles for this case control study were obtained through new genotyping and existing genetic data from a prior case control study of breast cancer using the Illumina Infinium Global Diversity Array or Multi Ethnic Genotyping Array. Primary analyses evaluated risk based on a recessive model, comparing women who carried two <em>APOL1</em> risk alleles to women who carried zero or one risk allele. We used multivariable logistic regression models to examine associations among 1473 participants with a history of preeclampsia (cases) and 5143 parous women who had not experienced preeclampsia (controls), and among 1296 participants who had a history of preterm birth and 5320 without such history.</div></div><div><h3>Results</h3><div>The odds ratio (OR) of preeclampsia for two <em>APOL1</em> risk alleles vs. zero or one risk allele was 0.99 (95 % confidence interval (CI): 0.74, 1.32) after adjustment for principal components, genotype platform, and age in 1995. For preterm birth, the comparable multivariable OR was 1.04 (95 % CI: 0.86, 1.25).</div></div><div><h3>Conclusions</h3><div>This large prospective study from a general population of Black women found no evidence of an association of <em>APOL1</em> genotype with risk of either preeclampsia or preterm birth.</div></div>","PeriodicalId":37085,"journal":{"name":"European Journal of Obstetrics and Gynecology and Reproductive Biology: X","volume":"25 ","pages":"Article 100365"},"PeriodicalIF":1.5,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11783058/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}